Decline in Value and Impairment of Business Assets and Investment Securities
First written in FY2020. 7 of 13 entries say "Restated". Latest entry: FY2025.
Kissei Pharmaceutical moved to the "Worse" side of this theme in 2021, 1 year after the typical company in this theme (2020).
The whole theme swung hardest in 2019: 23 of 50 companies on the "Worse" side.
26 other companies' latest entry also says "Materialised".
- FY2025MaterialisedAnnual report
「Impairment loss － 2,895」
The Group recognised an impairment loss of ¥2,895 million in the current consolidated fiscal year. This included ¥2,768 million relating to the marketing rights for Minirin Melt and desmopressin products, among other items, indicating that the risk of declines in the value of its holdings and impairment has materialised significantly. - FY2025-H1MaterialisedAnnual report
「Impairment loss － 128」
The Group recognised a ¥128 million impairment loss in the current interim consolidated accounting period, indicating that the decline in value and impairment risk of operating assets has materialised. - FY2024RestatedAnnual report
「The Group evaluates its operating assets, investment securities and other holdings every quarter in accordance with its group accounting policies. … Impairment losses may be recognised.」
The Group is reaffirming the impairment risk based on the market prices, net assets, business plans and other factors relating to operating assets and investment securities. - FY2024-Q2MaterialisedAnnual report
「Impairment losses on investment securities - 1」
The Group recognised a ¥1 million loss on valuation of investment securities in the cumulative second quarter of the current consolidated fiscal year, indicating that the risk of declines in the value of investment securities has materialised as a valuation loss. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The Group is reaffirming that there have been no material changes in the risk of declines in value and impairment of operating assets and investment securities. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The Group is reaffirming that there have been no material changes in the risk of declines in value and impairment of operating assets and investment securities. - FY2023-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
The Group is reaffirming that there have been no material changes in the risk of declines in value and impairment of operating assets and investment securities. - FY2022MaterialisedAnnual report
「Loss on valuation of investment securities 619」
The Group recognised a ¥619 million loss on valuation of investment securities in the current consolidated fiscal year, indicating that the risk of declines in the value of its holdings has materialised as a valuation loss. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The Group is reaffirming that there have been no material changes in the risk of declines in value and impairment of operating assets and investment securities. - FY2022-Q2MaterialisedAnnual report
「Loss on valuation of investment securities － 619」
The Group recognised a ¥619 million loss on valuation of investment securities in the cumulative second quarter of the current consolidated fiscal year, indicating that the risk of declines in the value of investment securities has materialised as a valuation loss. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The Group is reaffirming that there have been no material changes in the risk of declines in value and impairment of operating assets and investment securities. - FY2021-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Group is reaffirming that there have been no material changes in the risk of declines in value and impairment of operating assets and investment securities. - FY2020First statedAnnual report
「The Group evaluates its operating assets, investment securities and other holdings every quarter in accordance with its group accounting policies. For operating assets, impairment losses may be recognised if it becomes impossible to reasonably estimate the likelihood of recovery in the future. For investment securities and other holdings, impairment losses may be recognised based on market conditions for assets with market values, and, for unlisted shares and other assets without market values, after comprehensively considering the relevant company's net assets, future business plans and other factors.」
The risk of impairment based on the recoverability and market prices of operating assets and investment securities was explicitly identified for the first time as a business risk.